Aspira Women's Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
The proposed rule would allow for OvaWatchSM to be reimbursed at the same rate as Ova1® at $897 per test and will become final following a brief public comment period AUSTIN, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) ra
Source: yahoo.com